Scientists / Our Scientists

Domagoj Vucic

Senior Fellow, Early Discovery Biochemistry

Postdoc Mentor

"Blocking cell death to prevent tissue damage"

Years at Genentech

Publications

My laboratory studies the biological role of regulators of cell death and signaling pathways (e.g. ubiquitination-mediated regulation of NF-κB pathways), and their involvement in cellular processes triggered by TNF family ligands and other pro-inflammatory stimuli. As part of this effort we are studying how ubiquitination, phosphorylation and other post-translational modifications affect functional properties of mediators of various signaling pathways including apoptosis, necroptosis and NF-κB activation. To this end we are exploring the therapeutic potential of targeting select kinases and ubiquitin ligases for the treatment of uncontrolled inflammatory responses and/or enhancement of the survival of damaged tissues.

Postdoctoral Mentor

I cherish the opportunity to coach young scientists and guide their energy and enthusiasm for science into well organized thoughts and carefully planned experiments that will lay the foundation for their future scientific careers.

Featured Publication

RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.

Cell Death Differ. 2016 Sep 1;23(9):1565-76.

Newton K, Dugger DL, Maltzman A, Greve JM, Hedehus M, Martin-McNulty B, Carano RA, Cao TC, van Bruggen N, Bernstein L, Lee WP, Wu X, DeVoss J, Zhang J, Jeet S, Peng I, McKenzie BS, Roose-Girma M, Caplazi P, Diehl L, Webster JD, Vucic D.

View Abstract

We are investigating the physiological role of RIP family of kinases and inhibitors of apoptosis (IAP) proteins in modulation of immune responses. IAP proteins physically interact with a variety of mediators of inflammation and cell death and they regulate these signaling pathways by promoting ubiquitination of RIP1 and RIP2 kinases. In collaboration with other groups at Genentech we are developing genetic models and small-molecule compounds to evaluate the physiological contribution and therapeutic potential of distinct IAP proteins and RIP kinases in diseases impacted by inflammatory and cell death.

Genetic inactivation of RIP1 kinase activity in rats protects against ischemic brain injury

Cell Death and Disease,

Kimberly Stark; Tanya Goncharov; Eugene Varfolomeev; Luke Xie; Hai Ngu; Ivan Peng; Keith Anderson; Erik Verschueren; Meena Choi; Donald S. Kirkpatrick; Amy Easton; Webster; Brent McKenzie; Domagoj Vucic; Baris Bingol

Ubiquitination in the regulation of inflammatory cell death and cancer

Cell Death and Differentiation, ISSN: 13509047

Peter E. Cockram; Matthias Kist; Sumit Prakash; Si-Han Chen; Ingrid Wertz; Domagoj Vucic

Cell death pathways: intricate connections and disease implications

EMBO Journal, ISSN: 02614189

Matthias Kist; Domagoj Vucic

Regulation of Cell Death and Immunity by XIAP

Cold Spring Harbor Perspectives in Biology, ISSN: 19430264

Philipp J. Jost; Domagoj Vucic

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.

Domagoj Vucic

Senior Fellow, Early Discovery Biochemistry

Featured Publication

RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.